Skip to content
DraconiticResearch
Search Sources API
203,948 studies31 sourcesUpdated 4 min ago
Peer-reviewedCC BY 4.0Bone Reports

Changes in bone density and metabolism marker levels in type I Gaucher's disease following annual zoledronic acid hydrate administration: A case report

  • Hiroyuki Onuma1
  • Naoki Haraguchi2
  1. 1Department of Orthopaedic Surgery, Kawasaki Municipal Tama Hospital by Designated Administrator Educational Foundation, St. Marianna University School of Medicine, Kawasaki, Kanagawa, 214-8525, Japan
  2. 2Department of Orthopaedic Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, 216-8511, Japan
Read full textDOICite

Abstract

We present a rare case of type I GD with frequent bone complications. After multiple fractures the patient received 5 mg zoledronic acid hydrate, which improved TRACP-5b and P1NP levels. After 1 year, TRACP-5b levels increased significantly, and the patient received SRT therapy complemented with eldecalcitol for vitamin D deficiency. One year later, bone density had improved and bone metabolism markers remained within normal levels.

Osteoporosis treatment is a potential strategy for GD-related bone symptoms.

Related

  1. Changes in Core Temperature Following Administration of FC5, a Blood-Brain Carrier Fused with Neurotensin in Mice, Rats and Non-Human Primates.
    Alvaro Yogi, Etienne Lessard, Eric Brunette +6
    CellsPeer-reviewedCC BYFull textNeurologyEurope PMC
  2. Changes in Mood and Tryptophan Metabolism Following a 12-Week Endurance Exercise Combined with Time-Restricted Eating in Healthy Adults.
    Ulana Juhas, Dagmara Budnik-Przybylska, Andżelika Borkowska +10
    NutrientsPeer-reviewedCC BYFull textPsychiatry & mental healthEurope PMC
  3. Exacerbation of Pre-existing Hypothyroidism Following Enarodustat Administration in a Patient on Peritoneal Dialysis: A Case Report
    Kiho Yanagisawa, Yukihiro Wada, Shun Sakurabayashi +12
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. Ocular tissue distribution of Ocular Surface Immune Globulins Following Topical and Subconjunctival Administration: A Novel Strategy for Mitigation of ADC-Associated Ocular Toxicity
    Zeenal Dabre, Emily G. Krupa, Bhuvanachandra Pasupuleti +8
    Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and TherapeuticsPeer-reviewedLicence not statedFull text1 citedGeneral medicinePMC
  5. Stepwise administration of de novo ketogenic parenteral nutrition for refractory epilepsy during prolonged bowel rest following duodenal perforation
    Zaid Sheikh, Sarika Sewak, Danielle N. Mein +2
    JPGN reportsPeer-reviewedCC BYFull textPhysiologyEurope PMCPMC

Cite

BibTeXRIS
BibTeX
@article{onuma2026changes,
  title = {{Changes in bone density and metabolism marker levels in type I Gaucher's disease following annual zoledronic acid hydrate administration: A case report}},
  author = {Hiroyuki Onuma and Naoki Haraguchi},
  journal = {Bone Reports},
  year = {2026},
  month = oct,
  doi = {10.1016/j.bonr.2026.101962},
  url = {https://doi.org/10.1016/j.bonr.2026.101962},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Changes in bone density and metabolism marker levels in type I Gaucher's disease following annual zoledronic acid hydrate administration: A case report
AU  - Hiroyuki Onuma
AU  - Naoki Haraguchi
PY  - 2026
DA  - 2026/10/20
JO  - Bone Reports
DO  - 10.1016/j.bonr.2026.101962
UR  - https://doi.org/10.1016/j.bonr.2026.101962
AB  - We present a rare case of type I GD with frequent bone complications. After multiple fractures the patient received 5 mg zoledronic acid hydrate, which improved TRACP-5b and P1NP levels. After 1 year, TRACP-5b levels increased significantly, and the patient received SRT therapy complemented with eldecalcitol for vitamin D deficiency. One year later, bone density had improved and bone metabolism markers remained within normal levels.  Osteoporosis treatment is a potential strategy for GD-related bone symptoms.
SN  - 2352-1872
ER  -